-
Je něco špatně v tomto záznamu ?
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study
O. Fiala, S. Buti, K. Fujita, AG. de Liaño, W. Fukuokaya, T. Kimura, T. Yanagisawa, P. Giannatempo, M. Angel, A. Mennitto, J. Molina-Cerrillo, MT. Bourlon, A. Soares, H. Takeshita, F. Calabrò, C. Ortega, J. Kucharz, M. Milella, E. Seront, SH....
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, multicentrická studie
- MeSH
- antibakteriální látky terapeutické užití MeSH
- hormony kůry nadledvin terapeutické užití MeSH
- inhibitory protonové pumpy terapeutické užití MeSH
- karcinom z přechodných buněk farmakoterapie sekundární patologie mortalita MeSH
- lidé středního věku MeSH
- lidé MeSH
- monoklonální protilátky * terapeutické užití MeSH
- nádory močového měchýře farmakoterapie patologie mortalita MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- urologické nádory farmakoterapie patologie mortalita MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
Patients with metastatic urothelial carcinoma (mUC) are typically elderly and often have other comorbidities that require the use of concomitant medications. In our study we evaluated the association of concomitant use of antibiotics (ATBs), proton pump inhibitors (PPIs), corticosteroids, statins, metformin and insulin with patient outcomes and we validated the prognostic role of a concomitant drug score in mUC patients treated with enfortumab vedotin (EV) monotherapy. Data from 436 patients enrolled in the ARON-2EV retrospective study were analyzed according to the concomitant medications used at baseline. Finally, the patients were stratified into three risk groups according to the concomitant drug score based on ATBs, corticosteroids and PPIs. Statistical analysis involved Fisher exact test, Kaplan-Meier method, log-rank test, and univariate/multivariate Cox proportional hazard regression models. Inferior survival outcomes were observed in ATB users compared to non-users (OS: 7.3 months, 95%CI 5.0 - 12.3 vs 13.7 months, 95%CI 12.2 - 47.3, p = 0.001; PFS: 5.1 months 95%CI 3.3 - 17.7 vs 8.3 months, 95%CI 7.1 - 47.3, p = 0.001) and also in corticosteroid users compared to non-users (OS: 8.4 months, 95%CI 6.6 - 10.0 vs 14.2 months, 95%CI 12.7 - 47.3, p < 0.001; PFS: 6.0 months 95%CI 4.6 - 7.9 vs 8.9 months, 95%CI 7.2 - 47.3, p = 0.004). In the Cox multivariate analysis, the concomitant drug score was a significant factor predicting both OS (HR = 1.32 [95% CI 1.03 - 1.68], p = 0.026) and PFS (HR = 1.23 [95% CI 1.01 - 1.51], p = 0.044). Our findings suggest detrimental impact of concomitant use of ATBs and corticosteroids on survival outcomes and the prognostic utility of the concomitant drug score in previously treated mUC patients receiving EV.
Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Clinical Oncology Genitourinary Oncology Unit Alexander Fleming Institute Buenos Aires Argentina
Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic
Department of Medical and Surgical Sciences University of Bologna Bologna Italy
Department of Medical Oncology Ankara University Faculty of Medicine 06620 Ankara Türkiye
Department of Medical Oncology Azienda Ospedaliera Universitaria Maggiore Della Carit Novara Italy
Department of Medical Oncology Cliniques Universitaires Saint Luc Brussels Belgium
Department of Medical Oncology Hospital Ramón y Cajal Madrid Spain
Department of Medical Oncology Koc University Medical Faculty Istanbul Türkiye
Department of Medicine and Surgery University of Parma Parma Italy
Department of Oncology Faculty of Medicine and Dentistry Palacký University Olomouc Czech Republic
Department of Urology Kindai University Faculty of Medicine Osaka Japan
Department of Urology Saitama Medical Center Saitama Medical University Saitama Japan
Dipartimento di Oncologia Ospedale Michele E Pietro Ferrero Verduno ASLCN2 Alba E Bra Italy
Hospital Israelita Albert Einstein São Paulo SP Brazil
Hospital Sírio Libanês Brasília DF Brazil
Latin American Cooperative Oncology Group LACOG Porto Alegre Brazil
Medical Oncology 1 IRCCS Regina Elena National Cancer Institute Rome Italy
Medical Oncology IRCCS Azienda Ospedaliero Universitaria Di Bologna Bologna Italy
Medical Oncology Unit Macerata Hospital Macerata Italy
Medical Oncology Unit University Hospital of Parma Parma Italy
Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea
Taussig Cancer Institute Cleveland Clinic Cleveland OH USA
U O Oncologia Ospedale Di Civitanova Marche Civitanova Marche Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009839
- 003
- CZ-PrNML
- 005
- 20250429134940.0
- 007
- ta
- 008
- 250415s2025 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10585-025-10335-4 $2 doi
- 035 __
- $a (PubMed)39976819
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Fiala, Ondřej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University Prague, Alej Svobody 80, 304 60, Pilsen, Czech Republic. fialao@fnplzen.cz $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. fialao@fnplzen.cz
- 245 10
- $a Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study / $c O. Fiala, S. Buti, K. Fujita, AG. de Liaño, W. Fukuokaya, T. Kimura, T. Yanagisawa, P. Giannatempo, M. Angel, A. Mennitto, J. Molina-Cerrillo, MT. Bourlon, A. Soares, H. Takeshita, F. Calabrò, C. Ortega, J. Kucharz, M. Milella, E. Seront, SH. Park, D. Tural, G. Benedetti, Y. Ürün, N. Battelli, B. Melichar, A. Poprach, T. Buchler, J. Kopecký, V. Conteduca, FSM. Monteiro, F. Massari, S. Gupta, M. Santoni
- 520 9_
- $a Patients with metastatic urothelial carcinoma (mUC) are typically elderly and often have other comorbidities that require the use of concomitant medications. In our study we evaluated the association of concomitant use of antibiotics (ATBs), proton pump inhibitors (PPIs), corticosteroids, statins, metformin and insulin with patient outcomes and we validated the prognostic role of a concomitant drug score in mUC patients treated with enfortumab vedotin (EV) monotherapy. Data from 436 patients enrolled in the ARON-2EV retrospective study were analyzed according to the concomitant medications used at baseline. Finally, the patients were stratified into three risk groups according to the concomitant drug score based on ATBs, corticosteroids and PPIs. Statistical analysis involved Fisher exact test, Kaplan-Meier method, log-rank test, and univariate/multivariate Cox proportional hazard regression models. Inferior survival outcomes were observed in ATB users compared to non-users (OS: 7.3 months, 95%CI 5.0 - 12.3 vs 13.7 months, 95%CI 12.2 - 47.3, p = 0.001; PFS: 5.1 months 95%CI 3.3 - 17.7 vs 8.3 months, 95%CI 7.1 - 47.3, p = 0.001) and also in corticosteroid users compared to non-users (OS: 8.4 months, 95%CI 6.6 - 10.0 vs 14.2 months, 95%CI 12.7 - 47.3, p < 0.001; PFS: 6.0 months 95%CI 4.6 - 7.9 vs 8.9 months, 95%CI 7.2 - 47.3, p = 0.004). In the Cox multivariate analysis, the concomitant drug score was a significant factor predicting both OS (HR = 1.32 [95% CI 1.03 - 1.68], p = 0.026) and PFS (HR = 1.23 [95% CI 1.01 - 1.51], p = 0.044). Our findings suggest detrimental impact of concomitant use of ATBs and corticosteroids on survival outcomes and the prognostic utility of the concomitant drug score in previously treated mUC patients receiving EV.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 12
- $a monoklonální protilátky $x terapeutické užití $7 D000911
- 650 _2
- $a karcinom z přechodných buněk $x farmakoterapie $x sekundární $x patologie $x mortalita $7 D002295
- 650 _2
- $a nádory močového měchýře $x farmakoterapie $x patologie $x mortalita $7 D001749
- 650 _2
- $a urologické nádory $x farmakoterapie $x patologie $x mortalita $7 D014571
- 650 _2
- $a inhibitory protonové pumpy $x terapeutické užití $7 D054328
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a antibakteriální látky $x terapeutické užití $7 D000900
- 650 _2
- $a hormony kůry nadledvin $x terapeutické užití $7 D000305
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Buti, Sebastiano $u Medical Oncology Unit, University Hospital of Parma, Parma, Italy $u Department of Medicine and Surgery, University of Parma, Parma, Italy
- 700 1_
- $a Fujita, Kazutoshi $u Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan
- 700 1_
- $a de Liaño, Alfonso Gómez $u Department of Medical Oncology, Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas, Spain
- 700 1_
- $a Fukuokaya, Wataru $u Department of Urology, The Jikei University School of Medicine, 3-19-18 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Kimura, Takahiro $u Department of Urology, The Jikei University School of Medicine, 3-19-18 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Yanagisawa, Takafumi $u Department of Urology, The Jikei University School of Medicine, 3-19-18 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Giannatempo, Patrizia $u Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Giacomo Venezian 1, Milan, Italy
- 700 1_
- $a Angel, Martin $u Clinical Oncology, Genitourinary Oncology Unit, Alexander Fleming Institute, Buenos Aires, Argentina
- 700 1_
- $a Mennitto, Alessia $u Department of Medical Oncology, Azienda Ospedaliera Universitaria "Maggiore Della Carit", Novara, Italy
- 700 1_
- $a Molina-Cerrillo, Javier $u Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain
- 700 1_
- $a Bourlon, Maria T $u Department of Hemato-Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Escuela de Medicina, Mexico-Universidad Panamericana, Mexico City, Mexico
- 700 1_
- $a Soares, Andrey $u Hospital Israelita Albert Einstein, São Paulo, SP, Brazil $u Latin American Cooperative Oncology Group-LACOG, Porto Alegre, Brazil
- 700 1_
- $a Takeshita, Hideki $u Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
- 700 1_
- $a Calabrò, Fabio $u Medical Oncology 1-IRCCS Regina Elena National Cancer Institute, Rome, Italy
- 700 1_
- $a Ortega, Cinzia $u Dipartimento di Oncologia, Ospedale Michele E Pietro Ferrero-Verduno (CN) ASLCN2 Alba E, Bra, Italy
- 700 1_
- $a Kucharz, Jakub $u Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Warsaw, Poland
- 700 1_
- $a Milella, Michele $u Section of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University and Hospital Trust (AOUI) of Verona, 37134, Verona, Italy
- 700 1_
- $a Seront, Emmanuel $u Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
- 700 1_
- $a Park, Se Hoon $u Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 700 1_
- $a Tural, Deniz $u Department of Medical Oncology, Koc University Medical Faculty, Istanbul, Türkiye
- 700 1_
- $a Benedetti, Giovanni $u U.O. Oncologia, Ospedale Di Civitanova Marche, Civitanova Marche, Italy
- 700 1_
- $a Ürün, Yüksel $u Department of Medical Oncology, Ankara University Faculty of Medicine, 06620, Ankara, Türkiye
- 700 1_
- $a Battelli, Nicola $u Medical Oncology Unit, Macerata Hospital, Macerata, Italy
- 700 1_
- $a Melichar, Bohuslav $u Department of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
- 700 1_
- $a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00, Brno, Czech Republic
- 700 1_
- $a Buchler, Tomas $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, 150 06, Prague, Czech Republic
- 700 1_
- $a Kopecký, Jindřich $u Department of Oncology, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
- 700 1_
- $a Conteduca, Vincenza $u Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy
- 700 1_
- $a Monteiro, Fernando Sabino Marques $u Latin American Cooperative Oncology Group-LACOG, Porto Alegre, Brazil $u Hospital Sírio-Libanês, Brasília, DF, Brazil
- 700 1_
- $a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy $u Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy
- 700 1_
- $a Gupta, Shilpa $u Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
- 700 1_
- $a Santoni, Matteo $u Medical Oncology Unit, Macerata Hospital, Macerata, Italy
- 773 0_
- $w MED00007574 $t Clinical & experimental metastasis $x 1573-7276 $g Roč. 42, č. 2 (2025), s. 18
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39976819 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134935 $b ABA008
- 999 __
- $a ok $b bmc $g 2311305 $s 1246920
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 42 $c 2 $d 18 $e 20250220 $i 1573-7276 $m Clinical & experimental metastasis $n Clin Exp Metastasis $x MED00007574
- LZP __
- $a Pubmed-20250415
